Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE 38-week extension study of AIN457 in non-infectious posterior-segment uveitis
2009-015508-24Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious), non-infectious panuveitis (NIU) and 1 more comparing AIN457 continuation with Placebo (2 arms). Primary endpoint: Primary efficacy objective. Started Dec 2009; status: terminated.
02
Drugs
secukinumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)cyclitis
Beyond the preview
Go deeper on 2009-015508-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015508-24.